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Alzheimer’s disease (AD), a chronic neurodegenerative disease which is known to progress gradually, has 
now become a substantial health concern worldwide. Clinically, cognitive declination and progressive 
dementia are the main characteristics of AD while pathologically, Aß plaques and tau-neurofibrils are the 
hallmarks. The present literature search has suggested that oxidative stress is one of the most vital risk 
factors which can potentially lead to the development of AD. Oxidative stress is known to produce the 
reactive oxygen species which has a potential to increase in the structural and functional abnormalities 
in the glial cells of the brain and which could further lead to a cognitive decline, and subsequently, 
dementia. Hence to curb this oxidative stress in the glial cells, antioxidants have been proved to be of 
great help according to the literature search done in PubMed, Google Scholar, and Scopus. We included 
meta-analysis, systemic reviews, and original studies. Vitamins A, C, and E are an example of 
antioxidants that can be used as adjuvants in the treatment of AD. This article focuses on the 
contemporary literature search and presents forward the evidence-based banes of using Vitamins A, C, 
and E as an adjuvant therapy for preventing and treating AD. 
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Introduction and Background 
 
Alzheimer disease (AD) was described as “a 
peculiar severe disease process of the cerebral 
cortex” by Alois Alzheimer, which was based on 
the observations of one of his patients. He 
observed that the patient had a significant loss 
of memory with deteriorating psychological 
condition, without any relevant clinical history. 
Furthermore, he concluded that the patient’s 
postmortem examination revealed a significant 
decrease in the size of the cortex along with 
abnormal deposits in the neurons. Today, AD is 
a major public health concern, especially due to 
its total economic burden on the healthcare 
system. AD is also one of the front liner causes 
 
 
of dementia in patients having an age of more 
than 65 years. The other causes which followed 
AD in causing dementia are vascular dementia, 
frontotemporal dementia, Lewy body 
dementia, and alcohol-associated dementia.[1] 
 
Currently, approximately 25 million people are 
affected by dementia, of which majority are 
suffering from AD. AD has been impacting 
everyone’s day-to-day routine which not only 
includes the patients but also their caregivers 
and relatives, in both the developing and 
developed countries.[2] 
 
Due to the advent of medical science, developing 
countries have seen a rise in the life expectancy. 
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Hence, 65 years and above age group has become one of the 
most populous age groups of today. The statistics speaks that 
this segment of elders having an age 65 and above is stated to 
increase from 14% of the total population in 2012 to over 
20% of the entire population by 2030 in the United States. 
81% of Americans who are suffering from AD are aged 75 or 
above, highlighting the correlation between AD and 
advancing age. This rise has further contributed to an increase 
in the incidence and prevalence of AD. In 2016, there were 
approximately 476,000 new cases of AD in America alone, in 
the age group of 65 years and above. Moreover, every 66 
seconds, one person develops Alzheimer’s dementia which 
emphasizes the importance of this disorder. By 2030, it is 
projected that this incidence rate will rise to 615,000. The 
prevalence rate of AD was estimated to be around 5.4 million 
people in 2016, including 5.2 million having an age of 65 years 
and above. At present, one in every nine people (aged 65 and 
older) is seemed to be suffering from AD, while this number 
rises to one in three people in the age group of 85 and above. 
This prevalence rate of AD in those aged 65 and older is 
further projected to rise by 40% to 7.1 million until 2025 and 
13.8 million by 2050. Annually, the United States spends over 
$236 billion on AD patients alone, which could possibly rise 
further, if the AD is not prevented or cured.[3] 
 
AD is often seemed to be associated with the cognition and 
memory deficits which arise because of the formation of 
neurofibrillary tangles (NFTs) and deposition of the amyloid 
plaques in the nerve cells along with basal forebrain 
disruption of cholinergic neurons.[4] The cognitive decline 
related with AD pathogenesis is seemed to be attributed to 
the decrease in acetylcholine (A.Ch),[5] which also suggests 
that deficit of A.Ch can be devastating.[6] 
 
Therefore, a major evolution with regard to the treatment plan 
of AD should include an attempt to prevent the destruction of 
these cholinergic neurons, and if possible, the increment of the 
A.Ch levels in the brain should be main aim as well. In addition, 
several researchers have suggested that reactive oxygen species 
(ROS) is linked to the etiopathogenesis of AD. It causes a 
cumulative damage to the cellular macromolecules and also 
impairs the mitochondrial function. This further leads to a 
decrement in cellular energy production.[7] 
 
Pathogenesis of Oxidative Stress-Induced AD 
 
AD susceptibility to an oxidative damage can be linked to several 
factors which include relatively lesser concentration of the 
antioxidants, significantly increased levels of polyunsaturated 
fatty acids which is generally rapidly targeted by ROS, higher 
concentrations of metallic ions, and high usage of oxygen.[8] 
 
Oxidation can be fatal for the various cell components such as 
the proteins, carbohydrates, lipids, and the genetic constitution 
which includes the DNA and RNA.[9] It can not only accelerate 
 
the production of the inducible nitric oxide synthase (NOS) 
but also augment the activity of neuronal NOS (nNOS) which 
can further increase the production of NO. NO on interaction 
with the superoxide anions forms a highly reactive 
peroxynitrite anion which, subsequently, impairs the 
sulfhydryl groups of the cells.[10] Figure 1 depicts this process. 
 
Furthermore, oxidative stress has the potential to alter the protein 
structure. Impaired protein structure can further augment the 
oxidative damage. ROS causes these proteins to be oxidized and 
creates a modified structure which may get dimerized and 
aggregated.[11] These oxidized proteins, which are both structurally 
and functionally abnormal, gather as accumulates within the 
cytoplasm of the neurons and is seen in the form of NFT (tau 
aggregates) and Aß plaques.[12] Alternatively, Aß plaques can also 
cause increased formation of ROS which forms a vicious cycle. This 
pathway is shown in Figure 2. 
 
Aß (1–42) is a common species of Aß proteins seen in AD.[13] 
Aß (1–42) peptides are known for its toxicity which can be 
attributed to a residue of methionine at position 35.[14] 
Oxidation (by ROS) of methionine leads to the production of 
methionine sulfoxide, which may lead to the formation of 
methionine sulfone.[15] 
 
As a preventive mechanism, methionine sulfoxide is generally 
reduced into methionine by the action of methionine 




























Figure 2: Displaying correlation between oxidation 
and protein dimerization, thus forming a vicious cycle 
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also observed to be impaired in AD.[17] Hence, methionine’s 
oxidation can augment methionine sulfone production which 
is generally associated with aging and abnormal folding, 
further increasing the chance of developing AD. 
 
Methionine peroxide plays a crucial role in oxidative stress 
and toxicity caused by Aß (1–42) peptides. The oxidation of an 
atom present in the single pair of electrons in the methionine 
leads to the production of sulfuranyl radicals (MetS.+).[14,18] 
Sulfuranyl radical stimulates the production of ROS such as 
sulfoxides and superoxides by their interaction with the 
molecular oxygen.[19] 
 
This significant oxidative damage may be due to absence or 
reduced function of various antioxidant mechanisms in the 
body. 
 
Glutathione (GSH) is an important antioxidant, which can 
protect the brain tissues through detoxification of damaging 
ROS.[20] The most important element that leads to an 
increased oxidative stress in patients with AD is increased 
levels of GSH.[21] The other participants of the antioxidant 
mechanism, which also displays an important role, are 
catalase (CAT) and superoxide dismutase (SOD). 
 
SOD, also an antioxidant, is responsible for converting the toxic 
superoxide ions into hydrogen peroxide which is quite less 
toxic.[22] This reaction is augmented by CAT one step further, and 
H2O molecules are formed from hydrogen peroxide.[23] 
According to the recent researches, the levels of SOD and CAT 
are seemed to be diminished in the AD patients.[24] 
 
Glutathione reductase (GR) and glutathione peroxidase (GPx) 
also feature in cellular defense mechanism which counteracts 
the oxidative stress. Interestingly, GPx augments the metabolism 
of hydrogen peroxide and lipid hydroperoxides[25] while GR 
accelerates the reaction which helps in the regeneration of 
GSH.[26] To summarize, it is the oxidative stress coupled with the 
impaired cellular defense mechanism against the free radicals 
that are responsible for the development of  
AD. Figure 3 depicts AD pathogenesis. 
 
Hence, antioxidants could play a crucial role in AD prevention. 
Antioxidants, especially like Vitamins A, C, and E, are easily 
available in nature and could be considered as fighting force 
against this slow and deadly disorder. 
 
ACE Alzheimer’s: Vitamins A, C, and E (ACE) Therapy 
 
Evidence suggests that diet is a very important “modifiable” 
risk factor that plays a significant role in the development of 
AD or cognitive decline, depending on the food one 
consumes! There are certain foods that are rich in substances 


















Figure 3: Pathogenesis of Alzheimer’s disease  
(MG: Microglia; AS: Astrocyte; AP: Amyloid protein 
beta; NFT: Neurofibrillary tangles) 
 
 
Studies have shown that one can prevent the development of 
irreversible neurocognitive decline by consuming foods that 
are rich in fruits, green leafy vegetables while reducing the 
intake of processed foods, refined carbs, and diet that is high 
in saturated fats.[27] AD patients are always at risk of 
developing the nutritional deficiencies due to the 
physiological and psychological factors. 
 
Studies have shown significantly lower serum levels of certain 
essential fat and water -oluble vitamins in patients with AD as 
compared to individuals with intact neurocognitive function. [28] 
Conversely, serum levels and activity of antioxidants are found to 
be lower in subjects with AD, thus establishing a relationship 
between Vitamins A, C, and E, antioxidants, and incidence of 
AD.[29] 
 
Moreover, there is evidence to show that dietary intake of 
Vitamins A, C, and E increases antioxidants and influences 
activity against free radicals implicated in AD.[30] It has been 
observed that Vitamin A prevents the formation of beta-
amyloid plaques!.[31] Similarly, Vitamins C and E have also 
been proven to be beneficial in preventing/delaying the 
progression to irreversible neurocognitive decline.[1] 
 
Thus, it is essential to further explore these vitamins and their 
importance in the prevention and treatment of AD. 
 
Role of Vitamin A 
 
Vitamin A is essential for the development of the central nervous 
system, in childhood, adolescence as well as adulthood. It not 
only protects but also assists in the rejuvenation of the neuronal 
cells at the time of recovery from neurodegeneration.[32] 
 
In a study by Bourdel‐Marchasson et al.,[33] it was observed that 
the AD patients had substantial reduced levels of Vitamin A and 
beta-carotene in their CSF and blood. After stratification of 
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age, sex, and cardiovascular comorbidities, they found that the 
average alpha-tocopherol and retinol serum concentration was 
lower in AD patients as compared to that of the control subjects. 
 
The development of neurodegenerative disorders has shown 
to be influenced by Vitamin A and beta-carotene. A recent 
meta-analysis has shown that the serum levels of folic acid, 
vitamin A, vitamin B12, vitamin C and vitamin E were reduced 
in patients with AD.[34] A similar study by Foy et al. showed a 
significantly reduced level of plasma chain-breaking 
antioxidants, including Vitamins A, C, and E, in patient with 
dementia versus the control group (P < 0.01).[35] Inhibition of 
formation and destabilization of Aß fibrils are an additional 
effect of Vitamin A and beta-carotene.[32] 
 
Aß fibrils oligomerization is an important mechanism which often 
leads to neuronal toxicity in AD. However, Vitamin A 
supplementation has shown to be effective in decreasing the 
aggregation and oligomerization of Aß40 and Aß42 fibrils. It has 
also been observed that Vitamin A and beta-carotene prevent 
the decline of cognitive function in AD. Moreover, higher levels 
of these vitamins have been associated with better memory 
performance and spatial learning in these patients.[32,36,37] 
 
Role of Vitamin C 
 
The previous studies both in vivo and in vitro have condoned 
that Vitamin C plays a significant role in brain normal 
function. Decreased plasma levels despite adequate intake in 
patients further confirmed the belief of protective effects of 
Vitamin C in the spectrum of neurodegenerative diseases.[38] 
 
A study by Polidori et al. concluded that particular serum 
concentration of Vitamin C might be significantly important 
for the protection against AD and other clinical 
manifestations of vascular and cognitive aging.[39] Therefore, 
it can be inferred that antioxidant vitamins provide protection 
against oxidative stress-induced damage in AD. 
 
The development of AD can be halted by Vitamin C due to its 
actions on various aspects of AD’s pathology. Various studies, 
both in vivo and in vitro, concluded that Vitamin C helps in 
decreases the oxidative stress by hindering the Aß peptide 
oligomerization. 
 
Brain damage causes a reduction in the levels of antioxidants 
such as SOD and Vitamin C and causes oxidative stress in the 
tissue. Vitamin C supplementation seems to help in increasing 
the SOD levels, which consecutively not only decreases the 
oxidative stress but also prevents the brain injury further.[40] 
It has been hypothesized that even a normal dietary intake of 
Vitamin C can have a neuroprotective effect in AD patients. 
 
Furthermore, the cognitive decline has been observed to 
decrease significantly in the AD patients having an adequate 
 
Vitamin C intake.[41] Moreover, a recent observational study 
(n = 4740) which took place over 3 years concluded that extra 
supplementation with vitamins possessing antioxidant 
properties such as Vitamin C and E may be associated with a 
decrease in incidence and prevalence rates of AD.[42] 
 
Role of Vitamin E 
 
Vitamin E represents a cluster of 8 antioxidants composed of 
4 tocotrienols and 4 tocopherols. Studies have shown that 
reduced serum level of Vitamin E may be responsible for an 
increased risk of neurodegenerative disorders such as AD and 
mild cognitive impairment (MCI). Moreover, vitamin E 
metabolic products such as 5-nitro-γ-tocopherol are often 
seemed to increase substantially in AD and MCI.[43] 
 
If there is a deficiency of Vitamin E which is a potent 
antioxidant, it can result in extensive destruction of the 
neurons which has also been implicated before in cerebellar 
atrophy patients.[44] Aß plaques induced oxidative stress is 
considered to be a major risk factor for causing neuronal cell 
death and followed by neurodegeneration in AD. 
 
Vitamin E is also known as a scavenger of free radicals, and 
thus, is renders protection to neurons.[45] Vitamin E also 
provides protection against AD through various other 
methods. For example, glutamate formed by the 12-
lipoxygenase pathway induces excitatory cytotoxicity and 
subsequent neuronal cell death. This inflammation-induced 
neuronal death can be reduced by Vitamin E.[46] 
 
Furthermore, Vitamin E consumption has been associated with 
the regeneration of SOD, increased levels of which are shown to 
decline AD.[47] Among the different types or forms of Vitamin E, 
the best protection against AD is provided by a-tocopherols and 
γ-tocopherols.[48] A study by Berti et al. showed that an 
increased consumption of fresh fruit and vegetables, low-fat 
dairies, fish, whole grains, and reduction in intake of sweets, 
fried potatoes, high-fat dairies, butter, and processed meat was 
an AD-protective nutrient combination, essentially highlighting 
the importance of Vitamins E, A, and C in AD patients.[49] 
 
A recent study on 5395 individuals proved the protective role 
and effect of the dietary antioxidant supplementation against 
AD. Among all the antioxidants used, results indicated that 
the most substantial degree of protection versus AD and 
dementia (P = 0.02) was provided by Vitamin E. Moreover, 
only 30 international units of alpha-tocopherols if 
supplemented with normal diet could help in the prevention 
and treatment of AD.[50] 
 
Future Trails in the Treatment of AD 
 
Other antioxidants also play an important role in preventing 
AD. Probiotics, especially lactic acid bacteria, could help in 
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decreasing the oxidant level in the body.[51] Vitamins B, D, 
and K could also be an adjuvant therapy.[52] More research 
including meta-analysis and randomized control trials should 
be conducted so as to prove the importance of Vitamins E, A, 
and C in AD. We, therefore propose a term ACE Alzheimer’s as 





AD is a vital age-related neurodegenerative disorder. 
Antioxidants can help in fighting against the oxidative stress, 
which is an important mechanism responsible for the 
development and progression of this disease. The use of 
Vitamins E, A, and C as an antioxidant for adjuvant therapy for 
AD has been given consideration. Thus, further clinical 
research is necessary to study the potential of these vitamins 
for integration into clinical treatment and to accelerate the 
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